Sunrise's Scandium Refinery Just Got 2.6 Times More Expensive

Only fourteen assets currently produce scandium. Ten of them sit in China or Russia.

Not one produces it as a primary product.

That comes from screening the full global asset register as of 11 August: 135 assets across 21 countries carry scandium, fourteen are in production phase, and every one makes it as a by-product of rare earths, titanium, aluminium or nickel. Eight of the fourteen are refineries and concentrators rather than mines.

Which is why the United States Department of War's Office of Strategic Capital has conditionally committed up to US$400m to a single ASX-listed developer.

Sunrise Energy Metals published a feasibility study on 3 March 2026, putting Syerston's capital cost at approximately US$120m for 60 tonnes per annum of scandium oxide, with C1 cash costs of US$534/kg over a 32-year life.

The announcement lodged on 10 August revises that estimate to A$450 to A$475m, or US$315 to US$333m at the stated 0.70 rate.

Between 2.6 and 2.8 times higher, five months later.

The scope now includes a greenfield metallisation plant in the United States, a refinery capable of producing a broader range of scandium compounds, power generation brought onto the balance sheet rather than financed off it, and civil and utilities capital pulled forward to preserve a path to 180 tonnes per annum.

Sunrise says the revised estimate was presented to the OSC as the basis for the sizing of the proposed debt facility. The scope was rebuilt, then the loan was sized to it.

Washington did not fund a mine in New South Wales. It funded a supply chain with an American refining leg attached.

Two qualifiers that deserve more attention than they are getting.

The revised figure is not itself a finished study. Sunrise says the mine, the metallisation plant and the expansion capital sit at different levels of maturity and will be finalised over August. The number can move again before the board sees a final investment decision.

And this is a conditional commitment on a proposed 25-year facility, not an investment. Disbursement is phased against milestones, and each phase requires the company to deploy specified equity and to hold binding offtake.

Less searching. More strategising.™